SPONSOR
Hebei Senlang Biotechnology Inc., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 1, EARLY_Phase 1, Phase 2
Hebei Senlang Biotechnology Inc., Ltd. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors, UC, B-ALL.
The trial portfolio spans Phase 1, EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hebei Senlang Biotechnology Inc., Ltd.
How many clinical trials has Hebei Senlang Biotechnology Inc., Ltd. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Hebei Senlang Biotechnology Inc., Ltd., of which 3 are actively recruiting participants. These trials cover conditions including 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors, UC. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hebei Senlang Biotechnology Inc., Ltd. research focus on?
Hebei Senlang Biotechnology Inc., Ltd. clinical trials span 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors, UC, B-ALL. The research pipeline includes Phase 1, EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hebei Senlang Biotechnology Inc., Ltd. clinical trial?
To participate in a Hebei Senlang Biotechnology Inc., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hebei Senlang Biotechnology Inc., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Hebei Senlang Biotechnology Inc., Ltd.
NCT05388695 Phase 1
Recruiting
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
19 and 22+ B Cell Hematologic Tumors
NCT07435779 EARLY_Phase 1
Recruiting
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
UC
NCT07244406 Phase 2
Recruiting
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
B-ALL
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology